menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Chiesi Group Appoints 3 New Independent Non-Executive Directors

    PHARMAWEB

    Chiesi Study Highlights Challenge of Incorrect Use of Inhaler in UK

    PHARMAWEB

    Chiesi Reports Phase 3 Results of ELFABRIO® in Fabry Disease

    PR NEWSWIRE

    Chiesi`s New Biotech Center of Excellence Opens in Parma, Italy

    PR NEWSWIRE

    Chiesi USA Releases 2023 Sustainability Report

    GLOBENEWSWIRE

    Oak Hill Bio, Chiesi Enroll First BPD Prevention Phase 2b

    PR NEWSWIRE

    Chiesi Group signs MoU with Karolinska Institutet to tackle urgent challenges

    PHARMABIZ

    Chiesi Group Forges Allianc, Karolinska to Tackle Urgent Health Challenges

    PHARMIWEB

    Sanofi, Pfizer, AZ lead biopharma industry investment in France

    FIERCE PHARMA

    Gossamer Bio and Chiesi partner for pulmonary hypertension treatment

    PHARMACEUTICAL TECHNOLOGY

    Gossamer Bio and Chiesi Group collaborate on Seralutinib for pulmonary diseases.

    BUSINESSWIRE

    Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition

    REUTERS

    Chiesi champions new inhaler propellant to reduce carbon footprint

    PHARMACEUTICAL TECHNOLOGY

    Chiesi Global Presents Long-Term Data on Treatment with Velmanase Alfa

    PR NEWSWIRE

    Chiesi Group and Oak Hill Bio announce License and Development Agreement

    BUSINESSWIRE

    Chiesi Group and Oak Hill Bio announce License and Development Agreement

    PR NEWSWIRE

    Chiesi works with BBC to spread message about greener inhalers

    FIERCE PHARMA

    Chiesi Group signed a License Agreement with Haisco Pharmaceutical

    PR NEWSWIRE

    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    PM LIVE

    Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

    GLOBENEWSWIRE

    Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Team Up

    CONTRACT PHARMA

    Chiesi, Protalix`s Fabry disease approved as Elfabrio joins Fabrazyme

    ENDPTS

    Chiesi`s Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.

    FDA

    Europe signs off on Protalix, Chiesi`s Fabry disease treatment

    FIERCE PHARMA

    Chiesi Continues International Growth Surge

    CONTRACT PHARMA

    Chiesi, Affibody sign $637M respiratory disease collab

    FIERCE BIOTECH

    Pilloxa Signs a Agreement with Chiesi in Germany with a Value of SEK 1 million

    ACCESSWIRE

    Protalix & Chiesi gain positive opinion for pegunigalsidase alfa

    PHARMATIMES

    Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa

    BIOSPACE

    Chiesi Global Rare Diseases Presents Results from PIII BALANCE & BRIGHT Studies

    PR NEWSWIRE

    Chiesi gets FDA high five for enzyme replacement therapy Lamzede

    FIERCE PHARMA

    Chiesi`s Biologic Lamzede (Velmanase alfa) Receives Approval in the U.S.

    FDA

    After Amryt buy, Chiesi names Baxter vet Accogli its new CEO

    FIERCE PHARMA

    Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout

    FIERCE PHARMA

    Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc

    GLOBENEWSWIRE

    Chiesi Sues Aurobindo to Block Copies of Kengreal Anti-Clot Drug

    BLOOMBERG LAW

    Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

    PHARMAPHORUM

    After CRL, drug developer duo resubmits its experimental drug to the FDA

    ENDPTS

    Protalix & Chiesi Announce Resubmission of BLA to FDA for Pegunigalsidase Alfa

    PRNEWSWIRE

    Aptar and Chiesi Sign Contract to bring Best Disease Management Platform

    BUSINESSWIRE

    FDA starts review of first drug for alpha-mannosidosis, from Chiesi

    PHARMAPHORUM

    Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars

    GLOBENEWSWIRE

    NHS Scotland recommends Chiesi’s Trimbow for asthma

    PHARMAFILE

    Chiesi reinforces commitment to reducing emissions

    PHARMATIMES

    Chiesi Group joins White House pledge to decarbonize healthcare sector

    GLOBENEWSWIRE

    Chiesi tracks actions taken for a healthier, more sustainable future

    GLOBENEWSWIRE

    Chiesi enlists support for nose-to-brain biologic delivery push

    FIERCEPHARMA

    Chiesi supports painted hospitals project

    FIERCEPHARMA

    Chiesi Global Rare Diseases Announces Support for Jeffrey Modell Foundation

    PRNEWSWIRE

    Chiesi acquires pioneering therapeutic MAb portfolio against EMAP II

    PRNEWSWIRE

    CHIESI GROUP CONTINUES GROWTH

    PRNEWSWIRE

    Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease

    THEPHARMALETTER

    Chiesi USA donates more than $815,000 to local communities and nonprofits

    GLOBENEWSWIRE

    Protalix Bio, Chiesi Global Rare Diseases Submit MAA to EMA for PRX-102

    PRNEWSWIRE

    Chiesi Global Rare Diseases Announces Updated U.S. Prescribing FERRIPROX

    PRNEWSWIRE

    Protalix Biotherapeutics & Chiesi Global Rare Diseases Provide Regulatory Update

    PRNEWSWIRE

    Protalix sees a path for Fabry resubmission down the line

    FIERCEBIOTECH

    Chiesi accelerates its transition in favor of sustainable development

    BUSINESSWIRE

    Chiesi Accelerates Path Toward Full Sustainability Despite Covid-19 Pandemic

    BUSINESSWIRE

    Icario and ConnectureDRX Partner to Deliver a Seamless Enrollment Experience

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.